Extragenital gonorrhoea culture and test of cure at Western Sydney Sexual Health Centre
International Journal of STD & AIDS · 2023
DOI: 10.1177/09564624231183018 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of STD & AIDS, 2023. Verfasst von Nicholas B Comninos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Western Sydney Sexual Health Centre, Parramatta, New South Wales, Australia. Hauptthemen laut MEDLINE: Gonorrhea, Sexual Health. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
We read with interest the findings and recommendations of the 2020 BASHH National Clinical Audit: Management of infection with Neisseria gonorrhoeae (Ng) drawing on data from periods prior to and during the early Covid-19 pandemic. Western Sydney Sexual Health Centre (WSSHC) continued to serve a diverse outer metropolitan population in New South Wales, Australia throughout the pandemic. In line with key recommendations of the audit, we assessed internal gonorrhoea culture test (‘GCT’) and test of cure (‘TOC’) completion patterns for pharyngeal and rectal (‘extragenital’) gonorrhoea cases during the 2021 pandemic. We reviewed routinely collected electronic medical record (EMR) data (1/1//2021–31/12/2021, attendance reason ‘asymptomatic screening’, positive extragenital Ng nucleic-acid amplification tests (NAAT) and Ng treatment at WSSHC). GCTs (directly plated onto growth media) occurred ≤14 days following positive NAAT; NAAT-based TOCs ≤31 days following treatment. Self-collection was routine, however specific (self/clinician) collection-method data were unavailable, as were external/non-WSSHC testing data. Similar to the BASHH audit, median age was 32 years among 118 cases audited (57% throat/43% rectal NAATs). However, a higher proportion of our cohort were male (91%, all men who have sex with men ‘MSM’, offered extragenital testing per Australian guidelines). 57% were overseas-born, 2% Aboriginal/Torres Strait Islander, 18% with HIV, 6% injecting-drug use (any previous), 11% sexwork (any previous), 42% HIV Pre-exposure Prophylaxis use (previous 3 months). 51% had negative WSSHC throat and rectal Ng NAATs within the previous 12 months (median 3 months previously, 42% missing data). 93% (109/118) of cases received GCT, slightly higher than BASHH audit findings. Positivity was 27% (29/109), identical to another clinic-based study. Full susceptibility to Azithromycin occurred in 94%, Ceftriaxone in 100%, Ciprofloxacin in 15%.Median positive NAAT-GCT interval was 5 days (IQR 3–7). Positivity was 50% and 45% in shortest and longest NAAT-GCT interval quintiles, respectively. GCT completion was 93% (97/104); positivity 28% (27/97) among MSM; completion 86% (12/14); positivity 17% (2/12) among females. 2% received treatment regimens other than the Australian guideline-endorsed intramuscular Ceftriaxone 500 mg and oral Azithromycin 1g (rectal infection)/2g (pharyngeal infection), both due to allergy. 62% received concurrent WSSHC Syphilis±HIV serology within 3 months of gonorrhoea diagnosis (12% missing data). Partner notification discussion occurred in 87%. 60% (71/118) received TOC, slightly lower than reported in the BASHH audit. However, mirroring audit findings, 81% (38/47) without TOC defaulted/cancelled pre-booked TOC appointments (78% who defaulted received SMS prompting to rebook). Median treatment-TOC interval was 20 days (IQR 14–23); positivity 1% (1/71). MSM TOC completion was 61% (65/107), female completion 55% (6/ 11). 80% (94/118) had subsequent WSSHC extragenital NAATs 1–12 months post-treatment. 81% (38/47) without TOC subsequently tested (median 3 months post-treatment; positivity 3% (1/37). Re-audit (post-pandemic) may clarify the impact of Covid-19 restrictions on GCT and TOC. However, innovations to improve GCT positivity/yield might include updated collection/sampling instructions for clinicians/clients. Increasing staff familiarity/engagement with EMR pathology care-sets (introduced in late 2020) is expected to increase concurrent Syphilis/HIV testing. Finally, WSSHC plans to explore strategies to maximise TOC follow-up such as automated clinician/client prompting and/or take-home tests.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Western Sydney Sexual Health Centre, Parramatta, New South Wales, Australia.
- Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, Westmead, Sydney, New South Wales, Australia.
Zitieren
APA
Comninos, N. B., Varghese, S., & Power, M. (2023). Extragenital gonorrhoea culture and test of cure at Western Sydney Sexual Health Centre. International Journal of STD & AIDS. https://doi.org/10.1177/09564624231183018
Vancouver
Comninos NB, Varghese S, Power M. Extragenital gonorrhoea culture and test of cure at Western Sydney Sexual Health Centre. International Journal of STD & AIDS. 2023. doi:10.1177/09564624231183018
BibTeX
@article{Comninos2023,
author = {Comninos, Nicholas B and Varghese, Siju and Power, Melissa},
title = {Extragenital gonorrhoea culture and test of cure at Western Sydney Sexual Health Centre},
journal = {International Journal of STD & AIDS},
year = {2023},
doi = {10.1177/09564624231183018}
}
EUVIMED